Takeda, CSL stop COVID-19 plasma therapy development

April 6, 2021

The CoVIg-19 Plasma Alliance announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), failed to meet its endpoints. The CoVIg-19 Plasma Alliance, which was co-founded by CSL Behring and Takeda, was formed in April 2020 to help develop a potential plasma-derived therapy for people at risk for serious complications from COVID-19

The study aimed to determine whether an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine, CoVIg-19, could reduce the risk of disease progression when added to standard of care treatment including remdesivir in hospitalized adult patients at risk for serious complications. Analyses remain ongoing and NIAID and the INSIGHT Network intend to publish the full results of the trial soon.

Following the outcome of the ITAC trial, the CoVIg-19 Plasma Alliance will end. According to Takeda, the one-year collaboration enabled a renewed perspective toward pragmatic regulation based on scientific evidence and need, and provided a well-defined, legally compliant framework for future collaborative opportunities to address urgent public health needs.

Read the Takeda statement